Surrogate endpoints: the debate goes on
- 1 October 2001
- journal article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 10 (6), 493-496
- https://doi.org/10.1002/pds.655
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Are Surrogate Markers Adequate to Assess Cardiovascular Disease Drugs?JAMA, 1999
- Statistical issues for HIV surrogate endpoints: point/counterpointStatistics in Medicine, 1998
- Meta-analysis for the evaluation of potential surrogate markersStatistics in Medicine, 1997
- An approach to the validation of markers for use in AIDS clinical trials.Clinical Infectious Diseases, 1997
- Surrogate End Points in Clinical Trials: Are We Being Misled?Annals of Internal Medicine, 1996
- Modeling the Relationship of Survival to Longitudinal Data Measured with Error. Applications to Survival and CD4 Counts in Patients with AIDSJournal of the American Statistical Association, 1995
- Statistical validation of intermediate endpoints for chronic diseasesStatistics in Medicine, 1992
- Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or PlaceboNew England Journal of Medicine, 1991
- The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related ComplexNew England Journal of Medicine, 1987
- Pneumocystis cariniiPneumonia and Mucosal Candidiasis in Previously Healthy Homosexual MenNew England Journal of Medicine, 1981